ArticleCancer research2019
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Prenatal Characterization of Houge-Janssens Syndrome Type 2: A Case Report and Systematic Review of Fetal Phenotypes Associated With PPP2R1A Mutations.Molecular genetics & genomic medicine · 2025Pooled it
- Endogenous inhibitors of PP2A activate oncogenic and DNA damage response kinases in glioblastoma.Cancer letters · 2026Article
- The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.Journal of translational medicine · 2026Review
- Small Molecule Activator of Phosphatase PP2A Remodels Scaffold PR65 Structural Dynamics To Promote Holoenzyme Assembly.JACS Au · 2026Article
- Small molecule activator of phosphatase PP2A remodels scaffold PR65 structural dynamics to promote holoenzyme assembly.bioRxiv : the preprint server for biology · 2025Article
- Targeting PP2A in cancer: an underrated option.Journal of experimental & clinical cancer research : CR · 2025Review
- Regulatory mechanisms of PP2A complex assembly driven by physicochemical differences in A-subunit isoforms.Structure (London, England : 1993) · 2025Article
- Germline mutations in PPP2R1B in patients with a personal and family history of cancer.JCI insight · 2025Article
- STK39 inhibits antiviral immune response by inhibiting DCAF1-mediated PP2A degradation.Acta pharmaceutica Sinica. B · 2025Article
- Article
- Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer.Cancer research · 2025Article
- The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease.The Journal of clinical investigation · 2024Article
- The Impact of Mutational Hotspots on Cancer Survival.Cancers · 2024Article
- Altering phosphorylation in cancer through PP2A modifiers.Cancer cell international · 2024Review
- Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.PloS one · 2024Article
- Article
- A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer.Molecular biology reports · 2023Review
- PPP2R1A regulates migration persistence through the NHSL1-containing WAVE Shell Complex.Nature communications · 2023Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 8 institutions in 2 countries.
Sarah E TaylorDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Caitlin M O'ConnorDepartment of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio.ORCID https://orcid.org/0000-0002-7840-6399
Zhizhi WangDepartment of Biological Structure, University of Washington, Seattle, Washington.
Guobo ShenDepartment of Biological Structure, University of Washington, Seattle, Washington.
Haichi SongDepartment of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, University College London, London, United Kingdom.
Daniel LeonardDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Jaya SangodkarDivision of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Corinne LaVasseurSchool of Medicine, Case Western Reserve University, Cleveland, Ohio.
Stefanie AvrilDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Steven WaggonerDepartment of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio.
Kristine ZanottiDepartment of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio.ORCID https://orcid.org/0000-0002-4712-2852
Amy J ArmstrongDepartment of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio.ORCID https://orcid.org/0000-0002-5437-7319
Christa NagelDepartment of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio.
Kimberly ResnickDepartment of Obstetrics and Gynecology, MetroHealth, Cleveland, Ohio.
Sareena SinghDepartment of Obstetrics and Gynecology, Aultman Hospital, Canton, Ohio.
Mark W JacksonDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Wenqing XuDepartment of Biological Structure, University of Washington, Seattle, Washington.
Shozeb HaiderDepartment of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, University College London, London, United Kingdom.
Analisa DiFeoDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan.ORCID https://orcid.org/0000-0001-8319-6763
Goutham NarlaDivision of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. gnarla@med.umich.edu.
University Hospitals of Cleveland · USUniversity School · USUniversity of Michigan · USUniversity of Washington · USCase Western Reserve University · USThe London College · GBAultman Hospital · USMetroHealth · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MTargeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI REIZES, OFER · 2011 to 2020
$26.8MTissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ARONICA, MARK A · 2006 to 2019
$17.8MVERSICAN PROTEOLYSIS AND REGULATION OF VASCULAR SMOOTH MUSCLEP01HL107147 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI LAUER, MARK E · 2011 to 2017
$16.1MVIRALLY-INDUCED STAT-1, STAT-3 AND STAT-6M01RR018390 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI KIRWAN, JOHN P. · 2003 to 2007
$11.0MInstitutional Career Development CoreKL2TR002547 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI DWEIK, RAED A. · 2018 to 2022
$7.7MPREDOCTORAL TRAINING PROGRAM IN MOLECULAR THERAPEUTICST32GM008803 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI MIEYAL, JOHN J, NIEMAN, MARVIN THOMAS · 2001 to 2023
$4.2MStructural and molecular determinants of protein phosphatase 2A in Alzheimer's DiseaseR01CA240993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM, TAYLOR, DEREK JAMES · 2019 to 2023
$3.4MExamining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancerR01CA197780 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Analisa Virginia DiFeo · 2016 to 2026
$3.3MIdentification of a noval oncogene using validation-based insertional mutagenesisR01CA138421 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 2010 to 2020
$3.2MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MMechanisms of metabolic dysregulation in pulmonary hypertensionR01HL130209 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI DWEIK, RAED A. · 2016 to 2020
$2.9MNCATS NIH HHS KL2 TR002547NCATS NIH HHS TL1 TR002549NCI NIH HHS F30 CA224977NCI NIH HHS F30 CA224979NCI NIH HHS R01 CA138421NCI NIH HHS R01 CA181654NCI NIH HHS R01 CA197780NCI NIH HHS R01 CA240993NCRR NIH HHS M01 RR018390NCRR NIH HHS S10 RR031845NHLBI NIH HHS K23 HL068863NHLBI NIH HHS P01 HL081064NHLBI NIH HHS P01 HL103453NHLBI NIH HHS P01 HL107147NHLBI NIH HHS R01 HL130209NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM008803
Abstract
Somatic mutation of the protein phosphatase 2A (PP2A) Aα-subunit gene
Indexed as
Endometrial NeoplasmsCarcinogenesisFemaleHumansMutationNeoplasm Recurrence, LocalProtein Phosphatase 2Protein Phosphatase 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.